Transitioning from Heparin to Apixaban in Bilateral PE
Yes, you can discontinue the heparin infusion and transition directly to apixaban (Eliquis) in a hemodynamically stable patient with bilateral pulmonary embolism. 1
Direct Transition Protocol
Stop the heparin drip and start apixaban 10 mg orally twice daily immediately—no bridging or overlap is required. 1 The FDA-approved dosing for acute PE treatment begins with this loading dose for the first 7 days, then transitions to 5 mg twice daily for continued treatment. 1
Key Advantages of This Approach
No monitoring required: Unlike heparin (which requires aPTT checks every 4-6 hours) or warfarin (which needs INR monitoring), apixaban requires no laboratory monitoring once you confirm adequate renal and hepatic function. 1
Immediate therapeutic effect: Apixaban reaches peak anticoagulant effect within 3-4 hours of the first dose, providing seamless anticoagulation coverage when transitioning from heparin. 1
Superior safety profile: The American College of Chest Physicians recognizes that apixaban demonstrates similar efficacy to warfarin with reduced bleeding risk in VTE treatment. 2
Critical Pre-Transition Checklist
Before making the switch, verify these contraindications are absent:
Renal function: Creatinine clearance must be ≥15 mL/min (apixaban is contraindicated below this threshold). 2, 1
Hepatic function: Transaminases should be <2× upper limit of normal and total bilirubin <1.5× upper limit of normal. 2, 1
Active bleeding: No pathological bleeding should be present. 1
Hemodynamic stability: This approach is appropriate for stable patients; if your patient has massive PE with hemodynamic instability, consider thrombolysis or other interventions first. 3
Special Considerations
If Heparin-Induced Thrombocytopenia (HIT) is Suspected
If platelet count has dropped >50% or you suspect HIT, apixaban is an acceptable alternative to argatroban/bivalirudin in hemodynamically stable patients. 4, 3 The 2020 Anaesthesia guidelines state that apixaban has a good benefit/risk ratio for HIT treatment in patients without life-threatening thrombosis, with case series showing 0/21 major bleeds and 0/21 recurrent thromboses. 4, 3
However, if HIT is confirmed or highly suspected AND the patient has massive PE, extensive thrombosis, or hemodynamic instability, continue with argatroban or bivalirudin rather than switching to apixaban. 3, 5 Injectable anticoagulants are preferred in severe HIT presentations where rapid titration and monitoring are essential. 3
Drug Interactions to Avoid
If the patient is taking combined P-glycoprotein and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir), reduce the apixaban dose by 50%. 1 For patients who would receive 2.5 mg twice daily, avoid these drug combinations entirely. 1
Duration of Therapy
Continue apixaban 10 mg twice daily for 7 days, then reduce to 5 mg twice daily for at least 3 months total treatment duration. 1 After completing initial treatment, consider extended prophylaxis with 2.5 mg twice daily if the PE was unprovoked or if recurrence risk remains high. 1
Common Pitfalls to Avoid
Do not overlap heparin and apixaban: Unlike the warfarin transition (which requires 4-5 days of overlap), apixaban can be started immediately when the next heparin dose would be due. 1
Do not use prophylactic dosing (2.5 mg twice daily) for acute PE treatment: This is a critical error—acute PE requires the 10 mg twice daily loading dose. 1
Do not delay the transition unnecessarily: Once hemodynamic stability is confirmed and contraindications are ruled out, prolonging heparin infusion offers no benefit and increases nursing burden, line-related complications, and cost. 1, 6